drugset
drugset / Trial / NCT00880074

FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced Malignancies

NCT00880074 ↗

Phase 1 Completed 10 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelDiagnostic

Summary

This clinical trial studies fluorine F-18 fluorothymidine (FLT)-positron emission tomography (PET) in predicting response to chemotherapy in patients with advanced malignancies. FLT solution can help locate cancer cells inside the body. Diagnostic procedures, such as FLT-PET, may help find tumors and measure a patient's response to treatment.

Timeline

Start
2009-04-09
Primary completion
2022-02-04
Completion
2022-02-04

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-FLT Diagnostic / imaging agent — —

Indications

cancer